March 28, 2005
Whitaker Sues FDA Over CoQ10/Statin Issue
On March 4, JulianM. Whitaker, M.D., filed suit in U.S. District Court for the District ofColumbia against the Food and Drug Administration (FDA) for refusing to changethe warning labels on statin drugs to warn medical professionals and consumersabout the drugs adverse impact on body levels of coenzyme Q10 (CoQ10).Thesuit, filed by Emord & Associates, seeks a court order compelling FDA torequire labeling notices about statins depleting effects on CoQ10 levels andsuggesting CoQ10 supplementation to offset the impact. In addition, Whitaker isseeking declaratory and injunctive relief.
You May Also Like
Former FDA employees weigh in on gov’t shutdownSep 27, 2023
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Exercise recovery: Electrolytes, hydration and combating fatigue – SupplySide intensive webinarSep 22, 2023